BioCentury | Oct 16, 2014
Cover Story

DisABLing imatinib

...has been difficult because of the substantial homology between the isoforms. 6 Novartis' midostaurin and sotrastaurin...
...including PKCh. Midostaurin is in Phase III testing to treat acute myelogenous leukemia (AML), while sotrastaurin...
...Figure 8 in ref. 1.) A No companies have disclosed a PKCh-selective inhibitor. Midostaurin and sotrastaurin...
BioCentury | Aug 14, 2014
Distillery Therapeutics

Indication: Cancer

...inhibiting PRKCB with sotrastaurin could help treat CLL. In primary CLL cells, the PRKCB inhibitor sotrastaurin...
...and did not affect B cells from healthy subjects. In a mouse model of CLL, sotrastaurin...
...a Phase II trial to treat CLL and mantle cell lymphoma (MCL). Novartis has sotrastaurin (AEB071...
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

...unlikely to meet the study's primary endpoint Novartis AG (NYSE:NVS; SIX:NOVN) Discontinues development of sotrastaurin (AEB071...
BioCentury | Apr 30, 2012
Clinical News

Sotrastaurin: Development discontinued

...Novartis disclosed in its 1Q12 earnings that it discontinued development of sotrastaurin to prevent kidney and...
...of care. Details were not disclosed. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Sotrastaurin ( AEB071...
BioCentury | Apr 30, 2012
Clinical News

Sotrastaurin: Development discontinued

...Novartis disclosed in its 1Q12 earnings that it discontinued development of sotrastaurin to prevent kidney and...
...of care. Details were not disclosed. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Sotrastaurin ( AEB071...
BioCentury | Apr 25, 2012
Company News

Novartis seeks approval of imatinib for PAH

...recommending approval of Signifor pasireotide for Cushing's disease. Novartis also discontinued development of sotrastaurin ( AEB071...
...psoriasis after Phase II results did not show sufficient therapeutic benefit over standard of care. AEB071...
BioCentury | Dec 4, 2006
Clinical News

AEB071: Phase II started

...II testing of AEB071 to prevent graft rejection. Novartis AG (NVS; SWX:NOVN), Basel, Switzerland Product: AEB071...
Items per page:
1 - 7 of 7